-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-514592-17-00
4
2020-06-16
chronic myeloid leukemia
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2023-510537-28-00
5
2020-05-15
Multiple Myeloma
-
2022-501974-21-00
5
2020-04-01
Prevention of oral persistent infection caused by any of the human pap
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2023-509276-42-00
6
2019-10-30
Children and Adolescents with Cancers Harboring V600 mutation.
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2022-502658-15-00
5
2019-09-22
Resectable Stage II-IIIB Non-small cell lung cancer
-
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2024-511781-37-00
4
2019-04-16
YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
-
2023-509834-20-00
4
2019-03-13
untreated FLT3-mutated Acute Myeloid Leukemia
-
2024-511144-86-00
5
2019-02-14
Metastatic castration-resistant prostate cancer
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2023-505495-30-00
5
2019-02-01
Immunoglobulin A Nephropathy (IgAN)